title: Targeted therapy in pediatric low-grade glioma.
abstract: Collectively, pediatric low-grade gliomas account for most brain tumors reported in children. Surgery is typically curable for operable lesions. However, more effective therapies are required for inaccessible tumors, both to overcome refractory disease and to minimize the toxicity associated with conventional adjuvant chemotherapy and radiotherapy regimens. Recent years have witnessed rapid improvements in our understanding of the molecular pathogenesis of several childhood tumors, including low-grade gliomas. As a result, several novel compounds targeting and inhibiting critical components of molecular signaling pathways purported to be overactive in the disease have been developed. This article summarizes the most recent literature evaluating such novel targeted agents in childhood low-grade gliomas.
authors.affiliation: Department of Haematology/Oncology, Royal Manchester Children's Hospital, Oxford Road, Manchester, M13 9WL, UK, john-paul.kilday@cmft.nhs.uk.
authors.forename: John-Paul
authors.initials: JP
authors.lastname: Kilday
authors.forename: Ute Katharina
authors.initials: UK
authors.lastname: Bartels
authors.forename: Eric
authors.initials: E
authors.lastname: Bouffet
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D002648:Child; D005910:Glioma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D060787:Neoplasm Grading; D010372:Pediatrics; D059016:Tumor Microenvironment / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents